-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

Benzinga·01/22/2026 20:24:00
Listen to the news
Jefferies analyst Roger Song maintains Corvus Pharma (NASDAQ:CRVS) with a Buy and raises the price target from $13 to $42.